MetaCap

Dyne Therapeutics (DYN) vs Zai Lab (ZLAB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Zai Lab (ZLAB) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 5.0% versus a loss of 26.8%. Over five years, DYN leads with a +5.4% price change compared with -72.7% for ZLAB. Dyne Therapeutics is the larger company by market cap ($2.90 billion vs $2.63 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DYN-26.82%ZLAB+5.04%
+38%+1%-36%
Nov 21, 20251 yearNov 20, 2026
DYN-1.84%ZLAB-75.01%
+209%+56%-97%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DYN versus ZLAB key metrics
MetricDYNZLAB
Share price$15.50$21.03
Market cap$2.90B$2.63B
1-day change-3.31%-4.06%
YTD return-20.76%+19.22%
1-year return-26.82%+5.04%
5-year return+5.37%-72.67%
EPS (TTM)$-3.62$-1.80
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$460.16M
Revenue growth (YoY)—+15.33%
Net income (latest FY)$-446.21M$-175.54M
Gross margin—58.60%
Operating margin—-49.86%
Net margin—-38.15%
52-week high$27.31$29.02
52-week low$14.00$15.96
Distance from 52-week high-43.23%-27.53%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+121.48%+62.67%
Average volume2.94M991.34K
Shares outstanding187.39M124.84M
Employees3221,784
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ZLAB has outperformed DYN by 31.9 percentage points over the past year.

About Dyne Therapeutics

DYN stock →

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 322 employees

About Zai Lab

ZLAB stock →

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,784 employees

DYN vs ZLAB FAQ

Which is bigger, Dyne Therapeutics or Zai Lab?

Dyne Therapeutics (DYN) is larger, with a market capitalization of $2.90B compared with $2.63B for Zai Lab (ZLAB).

Which stock has performed better over the past year, DYN or ZLAB?

ZLAB returned +5.04% over the past 12 months, compared with -26.82% for DYN (price return, excluding dividends). Past performance does not predict future results.

Are Dyne Therapeutics and Zai Lab in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons